Skip to main content
. 2016 May 9;7(24):36971–36987. doi: 10.18632/oncotarget.9235

Figure 6. PI3K pathway decreases cleaved-Par-4-myc protein.

Figure 6

A. Cl-Par-4 cancer cells were treated with 10 or 15μM PI3K inhibitor (Wortmannin) for 24h. B. Cl-Par-4 cancer cells were treated with 0,5 or 1μM clinical PI3K inhibitor (NVP-BEZ235) for 24h. C. Endometrial cancers cells were treated with 10 or 20μg/mL of insulin to induce PI3K activity for 30 min. D. Cl-Par-4 cancer cells were pre-treated with 0,5μM clinical PI3K inhibitor (NVP-BEZ235) for 24h followed by a 24h treatment of 20μM cisplatin. The levels of p-AKT (Ser473), total AKT and cl-Par-4-myc were determined in treated cells using western blot analysis. GAPDH or β-actin were used as loading controls. Results shown are representative of three independent experiments.